Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Rediscovering Imagination in Adulthood: Individual Creative Excursions - 2Exemplary Fragrances: A Manual for Notorious Scents
- 3‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- 4SF Chinatown's historic Empress of China building being revived into cultural campus
- 5Crew-11 astronauts undock in 1st-ever medical evacuation from the International Space Station (video)
- Ukraine apologizes to Finland for crashed drones
- 'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Spain’s Picos de Europa: What to see and do in ‘the world’s most beautiful place’
- UPM Adhesive Materials plans new facility near New Delhi, India
- See the 'amazing' photos of Earth taken on historic Artemis II moon mission
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- America's Confided in Fridge in 2024
